Ken Griffin 89bio, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$7.36 - $9.66 $103,040 - $135,240	14,000 Added 69.65%	34,100 $252,000
Q2 2024 Aug 14, 2024	SELL	$7.31 - $10.9 $491,963 - $733,570	-67,300 Reduced 77.0%	20,100 $161,000
Q1 2024 May 15, 2024	SELL	$8.13 - $13.77 $144,714 - $245,106	-17,800 Reduced 16.92%	87,400 $1.02 Million
Q4 2023 Feb 14, 2024	BUY	$6.66 - $16.03 $352,980 - $849,590	53,000 Added 101.53%	105,200 $1.18 Million
Q3 2023 Nov 14, 2023	BUY	$15.06 - $19.41 $504,510 - $650,235	33,500 Added 179.14%	52,200 $805,000
Q2 2023 Aug 14, 2023	SELL	$14.15 - $22.03 $890,035 - $1.39 Million	-62,900 Reduced 77.08%	18,700 $354,000
Q1 2023 May 15, 2023	BUY	$10.48 - $16.94 $234,752 - $379,456	22,400 Added 37.84%	81,600 $1.24 Million
Q4 2022 Feb 14, 2023	SELL	$5.52 - $12.73 $162,288 - $374,262	-29,400 Reduced 33.18%	59,200 $753,000
Q3 2022 Nov 14, 2022	BUY	$3.02 - $7.0 $172,140 - $399,000	57,000 Added 180.38%	88,600 $513,000

158

108M

73.6K

1.19M

Ticker ETNB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,484,500
Market Cap $365M
Description
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.